What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing scrutiny...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Mr. Ruparel advises clients on the economics of the life sciences industry. He has served as an expert witness and non-testifying expert on issues including antitrust liability, class certification, and damages.
Archan regularly provides economic expertise in disputes, including antitrust matters, intellectual property litigation, and commercial disputes. He has advised pharmaceutical companies, pharmacy benefits managers, insurers, and regulators. He has presented before federal and state regulators and provided analysis in disputes before regulatory boards, judges, arbitration panels, and juries. Mr. Ruparel has also assisted life sciences companies and counsel on complex questions involving development, pricing and market access, loss of exclusivity, and follow-on products.
Prior to joining CRA, Mr. Ruparel served in the Bureau of Economics of the Federal Trade Commission. At the FTC, Mr. Ruparel conducted a study of credit-based insurance scores and pharmaceutical direct-to-consumer advertising as well as investigations and litigation involving hospital mergers, telemarketing, and fair lending.
Mr. Ruparel serves on CRA’s pro bono committee.
